==StableCoinX (USDE) : 2-month performance,

StablecoinX Inc., a stablecoin infrastructure company, focuses on the Ethena digital dollar ecosystem. It offers infrastructure services, stablecoin middleware software, and stablecoin distribution services. The company is based in Frisco, Texas.

Sector: Financial Services

Industry: Capital Markets

https://stablecoinx.com

StablecoinX completed its public market debut on June 26, 2026, via a business combination with the special purpose acquisition company (SPAC) TLGY Acquisition Corp. Its Class A common stock trades on Nasdaq under the ticker symbol USDE. 

Public Listing Details

Transaction Date: June 26, 2026 (following the closure of the merger with TLGY Acquisition Corp. on June 25, 2026).
Exchange / Ticker: Nasdaq Capital Market under USDE (Class A shares) and USDEW (warrants).
Core Focus: Functioning as a public stablecoin infrastructure firm and treasury vehicle centered around the Ethena Labs ecosystem, holding a multi-year treasury strategy in ENA governance tokens.
Leadership: Led by CEO Edward Chen

EquipmentShare (EQPT) reported earnings on Wed 12 Aug 2026 (a/h)

IPO: Jan 23, 2026 

** charts before earnings ** 

 ** 1 week  after earnings **

 ** 1 week  later ** 

Total revenue of $1,449 million for the second quarter and $4,952 million on a TTM(1) basis.

Rental Segment(2) revenue of $908 million for the second quarter, an increase of 39% year over year, and on a TTM(1) basis $3,189 million, an increase of 37% year over year.

Net income of $19 million for the second quarter and net income of $62 million on a TTM(1) basis.

Adjusted Net Income for the second quarter of $43 million and Adjusted Net Income of $103 million on a TTM(1) basis.

Adjusted Core EBITDA(3) of $531 million for the second quarter and $1,911 million on a TTM(1) basis.

Mature rental locations adjusted EBITDA margins were 55% on a TTM(1) basis.

430 locations with 23 new locations opened during the second quarter.

(1) TTM refers to the trailing twelve month period ended June 30, 2026. See “Trailing Twelve Month Financial Information” for additional information on TTM.

(2) Refers to the Equipment Rental and Services Operations segment.

(3) Adjusted Core EBITDA is a non-GAAP measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

About EquipmentShare

Founded in 2015 and headquartered in Columbia, Missouri, EquipmentShare is a nationwide construction technology and equipment solutions provider dedicated to transforming the construction industry through innovative tools, platforms and data-driven insights. By empowering contractors, builders and equipment owners with its proprietary technology, T3Ⓡ, EquipmentShare aims to drive productivity, efficiency and collaboration across the construction sector. With a comprehensive suite of solutions that includes a fleet management platform, telematics devices and a best-in-class equipment rental marketplace, EquipmentShare continues to lead the industry in building the future of construction.

Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65

Founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 

Headquartered in Cambridge, MA
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.